Galaxy Biomedical Investment Co.,Ltd. Posted 5 Million Yuan Net Loss in First Half of 2022

Galaxy Biomedical Investment Co.,Ltd. (北海银河生物产业投资股份有限公司) (000806.SZ) reported a net loss of 5 million yuan in the first half of 2022, narrowing 97.3% year-on-year.

Meanwhile, the company posted 779.8 million yuan in revenue, up 58.5% year-on-year.

At the end of the reporting period, it had 1.7 billion yuan in total assets and 2.7 billion yuan in total liabilities, with a liability-to-asset ratio of 151.6%.